BOSTON - Compass Therapeutics, Inc. (NASDAQ: CMPX) shares gained 2.7% after the clinical-stage oncology company reported progress across its pipeline and provided a business update for 2024. While the ...

D. Boral Capital reaffirmed their buy rating on shares of Compass Therapeutics (NASDAQ:CMPX – Free Report) in a report published on Tuesday,Benzinga reports. The firm currently has a $32.00 price ...

Highlights,Maze Therapeutics is a clinical-stage biopharmaceutical company focused on precision medicines for renal, ...

In 2024, we established a strong foundation for what we expect will be a transformational year ahead for Compass,” said Thomas Schuetz, MD, ...

Top-line Phase 2/3 data readout for COMPANION-002, evaluating tovecimig (CTX-009 - a DLL4 x VEGF-A bispecific antibody) in patients with biliary tract cancer (BTC), is on track for the end of the ...

HLS Therapeutics Inc. ("HLS" or the "Company") , announces that it will release its Q4 and fiscal 2024 financial results on Thursday, March 13, 2025. The Company will hold a conference call that same ...

Research analysts at Guggenheim began coverage on shares of Compass Therapeutics (NASDAQ:CMPX – Get Free Report) in a research note issued on Monday, MarketBeat reports. The firm set a “buy” rating ...

Fresh Tracks Therapeutics, Inc. ("Fresh Tracks" or the "Company") announced today an update on its previously announced, planned dissolution and its process for distributing cash to its stockholders.

Fintel reports that on February 24, 2025, Guggenheim initiated coverage of Compass Therapeutics (NasdaqCM:CMPX) with a Buy recommendation. Analyst Price Forecast Suggests 266.05% Upside As of February ...

Compass Therapeutics (CMPX) stock was up 8% in afternoon trading Monday after Guggenheim initiated coverage of the stock with a buy rating ahead of upcoming data. Read more here.

Compass Therapeutics' lead candidate, tovecimig, shows mixed data in various trials, with a significant upcoming phase 3 ...